Navigation Links
Dialysis Corporation of America Announces Acquisition of Maryland Dialysis Center
Date:1/5/2009

LINTHICUM, Md., Jan. 5 /PRNewswire-FirstCall/ -- Dialysis Corporation of America (Nasdaq: DCAI) announced the acquisition of a dialysis center in Hyattsville, Maryland, located at the St. Thomas More Nursing and Rehabilitation Center, where it can treat patients from both within the St. Thomas More Center, as well as the surrounding community.

This new center has 24 treatment stations and is currently caring for approximately 145 dialysis patients. The company is considering adding six more stations to the facility, which will accommodate up to an additional 36 patients.

President & CEO Stephen Everett commented "This newest center in Maryland is strategic to DCA as we begin 2009. It marks our fourth facility located on the campus of a skilled nursing facility, and our sixth in Maryland, which remains a focused market for DCA. Additionally, we are very fortunate to be inheriting a great group of caregivers in a community with several excellent nephrologists."

Dialysis Corporation of America owns and operates freestanding kidney hemodialysis centers located in Georgia, Maryland, New Jersey, Ohio, Pennsylvania, South Carolina, and Virginia, and provides in-hospital dialysis services on a contract basis to certain hospitals located in the those states. The company provides patients with their choice of a full range of quality in- center, acute or at-home hemodialysis services.

This release contains forward-looking statements that are subject to risks and uncertainties that could affect the business and prospects of the company and cause actual results and plans to differ materially from those anticipated. Those factors include, but are not limited to, increases in interest rates, the possible need for and availability of additional financing, the company's satisfying the covenants and conditions of its credit facility, certain delays beyond the company's control with respect to future business events, the highly competitive environment in the establishment and operation of dialysis centers, the ability to develop or acquire additional dialysis facilities, whether patient bases of the company's dialysis facilities can mature to provide profitability, the extensive regulation of dialysis operations, government rate determination for Medicare reimbursement, pricing pressure from private payors, and other risks detailed in the company's filings with the SEC, particularly as described in the company's annual report on Form 10-K for the fiscal year ended December 31, 2007. The historical results contained in this press release are not necessarily indicative of future performance of the company.

Other Dialysis Corporation of America press releases, corporate profile, corporate governance materials, quarterly and current reports, and other filings with the Securities and Exchange Commission are available on Dialysis Corporation of America's internet home page: http://www.dialysiscorporation.com.

CONTACT: For additional information, you may contact Dialysis Corporation of America, 1302 Concourse Drive, Suite 204, Linthicum, MD 21090; Telephone Number (410) 694-0500; Attention: Investor Relations.


'/>"/>
SOURCE Dialysis Corporation of America
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Major North American breakthrough for dialysis patients
2. Overnight Dialysis Saves Lives: Study
3. Dialysis Corporation of America Reports Third Quarter 2008 Results
4. Dialysis Corporation of America Announces $25 Million Credit Facility
5. NxStage(R) Achieves Milestone with 3,000 End-Stage Renal Disease Patients Receiving Daily Home Hemodialysis Therapy
6. Gulf Coast Dialysis Caregivers, Volunteers Brace for Hurricane Ike; Prepare to Maintain Power, Continued Access for Patients to Life-Saving Treatment
7. Dialysis Patient Citizens Welcomes New Members to Board of Directors
8. Frost & Sullivan Honours Redsense Medical With the 2008 European Hemodialysis Emerging Company of the Year Award
9. Dialysis Corporation of America Reports Second Quarter 2008 Results
10. Bone Disease Test Shows Death Risk for Dialysis Patients
11. Automated, Wearable Kidney Offers Continuous Dialysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... April 29, 2016 , ... ... Foundation, the national charitable foundation serving the footwear industry, has broken all previous ... more than 130 companies across 23 states during the months of April and ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Awakening , announces the addition Onnit brand Alpha BRAIN and New Mood Daily-Stress ... Onnit brain and mood optimization products to the store is just one more ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, ... the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural ... (R - Cumming), offers a 70% tax credit to individuals and corporations which donate ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... and author of best seller "LOVE, MEDICINE and MIRACLES") addresses touchy topics related ... 2016 and podcasted thereafter . Dr. Bernie Siegel, author of a plethora ...
(Date:4/29/2016)... STAMFORD, CONNECTICUT (PRWEB) , ... April 29, 2016 , ... ... 5K Run/Walk” at Cove Island Park on Sunday, with sunny skies, a light breeze ... event, raising nearly $33,000. , The 5k Run and Walk and 1-mile ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ... on the development of oral drug delivery systems, announced today ... conference, presented by Joseph Gunnar & Co. LLC, ... York . Nadav Kidron , CEO of Oramed, ... Presentation Details:   PIONEERS 2016, presented by ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... April 27, 2016   ... Growth in Recurring Consumable Sales  Clinical sales ... Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, ... sales for the first quarter ended March 31, 2016 ... execution of its commercial strategy. First Quarter ...
Breaking Medicine Technology: